Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Berger

Showing results (981-990 of 1,161) with videos related to

Pageof 117
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2019
Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung AdenocarcinomaJian Zhou, Francisco Sanchez-Vega, Raul Caso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2024
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT StudyJames W Smithy, Hannah L Kalvin, Fiona D Ehrich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancerU A Matulonis, G M Wulf, W T Barry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2018
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune TherapiesJames J Harding, Subhiksha Nandakumar, Joshua Armenia, et al.
European Urology|October 7, 2018
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant ChemotherapyEugene J Pietzak, Emily C Zabor, Aditya Bagrodia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2017
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct PathogenesisMatthew T Chang, Alexander Penson, Neil B Desai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2021
Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and PathwaysSmita Sihag, Samuel C Nussenzweig, Henry S Walch, et al.
Science Translational Medicine|July 31, 2020
Cellular senescence impairs the reversibility of pulmonary arterial hypertensionDiederik E van der Feen, Guido P L Bossers, Quint A J Hagdorn, et al.
Cancer|June 24, 2020
Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinomaCaitlin A McIntyre, Sharon A Lawrence, Allison L Richards, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 9, 2018
Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancerSebastian Mondaca, Matthew Margolis, Francisco Sanchez-Vega, et al.
Pageof 117

Showing results (981-990 of 1,161) with videos related to

Sort By:
Pageof 117
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2019
Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung AdenocarcinomaJian Zhou, Francisco Sanchez-Vega, Raul Caso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2024
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT StudyJames W Smithy, Hannah L Kalvin, Fiona D Ehrich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancerU A Matulonis, G M Wulf, W T Barry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2018
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune TherapiesJames J Harding, Subhiksha Nandakumar, Joshua Armenia, et al.
European Urology|October 7, 2018
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant ChemotherapyEugene J Pietzak, Emily C Zabor, Aditya Bagrodia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2017
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct PathogenesisMatthew T Chang, Alexander Penson, Neil B Desai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2021
Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and PathwaysSmita Sihag, Samuel C Nussenzweig, Henry S Walch, et al.
Science Translational Medicine|July 31, 2020
Cellular senescence impairs the reversibility of pulmonary arterial hypertensionDiederik E van der Feen, Guido P L Bossers, Quint A J Hagdorn, et al.
Cancer|June 24, 2020
Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinomaCaitlin A McIntyre, Sharon A Lawrence, Allison L Richards, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 9, 2018
Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancerSebastian Mondaca, Matthew Margolis, Francisco Sanchez-Vega, et al.
Pageof 117